AVITA Medical, Inc. Stock News

AVITA Medical will report first quarter 2024 financial results after the close on May 13, 2024, and host a webcast that day at 1:30 p.m. Pacific Time.

VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana

AVITA Medical, Inc. (RCEL) Q4 2023 Earnings Call Transcript

VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cell

VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cell

AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the supple

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.

VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of f

AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Offic

VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class device

The FDA is asking for more information regarding Avita's Recell Go device. The Recell Go is a more automated version of an already approved product for Avita.

VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic

VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic

AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer David O

AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force